Evaluation of the thrombin generation potential of a recombinant factor IX Fc fusion protein (rFIXFc) in a phase 3 multi-national clinical trial

被引：0
|
作者：
Yang Buyue [1 ]
Jiang, Haiyan [1 ]
Luk, Alvin [1 ]
Pierce, Glenn F. [1 ]
Sommer, Jurg M. [1 ]
机构：
[1] Biogen Idec Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [1] Evaluation of the thrombin generation potential of a recombinant factor VIII Fc fusion protein (rFVIIIFc) in a phase III multi-national clinical trial
    Buyue, Y.
    Jiang, H.
    Luk, A.
    Pierce, G. F.
    Sommer, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 228 - 228
  • [2] Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc (rFIXFc) fusion protein in animals
    Dumont, Jennifer A.
    Loveday, Ken
    Light, David R.
    Pierce, Glenn F.
    Jiang, Haiyan
    HAEMOPHILIA, 2014, 20 : 20 - 20
  • [3] REAL WORLD PROPHYLAXIS WITH RECOMBINANT FACTOR IX FC FUSION PROTEIN (RFIXFC) - LONGITUDINAL FOLLOW UP IN A NATIONAL COHORT
    O'Donovan, M.
    Bergin, C.
    Quinn, E.
    Singleton, E.
    Benson, J.
    Bird, R.
    Byrne, M.
    Duggan, C.
    Gilmore, R.
    Ryan, K.
    O'Donnell, J. S.
    O'Connell, N. M.
    HAEMOPHILIA, 2021, 27 : 114 - 114
  • [4] Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
    Diao, Lei
    Li, Shuanglian
    Ludden, Thomas
    Gobburu, Jogarao
    Nestorov, Ivan
    Jiang, Haiyan
    CLINICAL PHARMACOKINETICS, 2014, 53 (05) : 467 - 477
  • [5] Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
    Lei Diao
    Shuanglian Li
    Thomas Ludden
    Jogarao Gobburu
    Ivan Nestorov
    Haiyan Jiang
    Clinical Pharmacokinetics, 2014, 53 : 467 - 477
  • [6] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
    Powell, Jerry S.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Valentino, Leonard A.
    Mahlangu, Johnny N.
    Josephson, Neil C.
    Perry, David
    Manco-Johnson, Marilyn J.
    Apte, Shashikant
    Baker, Ross I.
    Chan, Godfrey C.
    Novitzky, Nicolas
    Wong, Raymond S.
    Krassova, Snejana
    Allen, Geoffrey
    Jiang, Haiyan
    Innes, Alison
    Li, Shuanglian
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Nugent, Karen
    Vigliani, Gloria
    Brennan, Aoife
    Luk, Alvin
    Pierce, Glenn F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2313 - 2323
  • [7] Effect of Sampling Duration on Pharmacokinetic (PK) Parameters of Recombinant Factor IX FC Fusion Protein (rFIXFc) in the Phase 3 B-LONG Study
    Berntorp, E.
    Mei, B.
    Lethagen, S.
    Li, S.
    HAEMOPHILIA, 2016, 22 : 44 - 44
  • [8] Comparative field study evaluating the activity of recombinant Factor IX - Fc fusion protein (rFIXFc) in plasma samples at clinical haemostasis laboratories
    Sommer, J.
    Buyue, Y.
    Peters, R. T.
    Jiang, H.
    Gray, E.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 828 - 829
  • [9] Evaluation of whole-blood clotting activity of recombinant factor IX Fc fusion protein by ROTEM analysis in a multi-centre Phase III clinical trial
    Sommer, Jurg M.
    Driessler, Frank
    Luk, Alvin
    Pierce, Glenn F.
    Jiang, Haiyan
    HAEMOPHILIA, 2014, 20 : 21 - 21
  • [10] Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort
    O'Donovan, Mairead
    Bergin, Catherine
    Quinn, Eimear
    Singleton, Evelyn
    Roche, Sheila
    Benson, Julie
    Bird, Rachel
    Byrne, Mary
    Duggan, Cleona
    Gilmore, Ruth
    Ryan, Kevin
    O'Donnell, James S.
    O'Connell, Niamh M.
    HAEMOPHILIA, 2021, 27 (04) : 618 - 625
12345